Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.32 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612613 | 1.00 | PIK3CA (0.37) | PIK3CACREBBPGPR142PRMT5KCNH2 | |
| SCHEMBL6126540 | 0.91 | PIK3CA (0.47) | PIK3CACREBBPGPR142 | |
| SCHEMBL6126917 | 0.91 | PIK3CA (0.47) | PIK3CACREBBPGPR142 | |
| SCHEMBL9612603 | 0.86 | PIK3CA (0.39) | PIK3CACREBBPPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612604 | 0.86 | PIK3CA (0.45) | PIK3CACREBBPPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612578 | 0.82 | PIK3CA (0.46) | PIK3CAPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612492 | 0.81 | PIK3CA (0.45) | PIK3CACREBBPPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612615 | 0.81 | PIK3CA (0.45) | PIK3CAPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612609 | 0.81 | PIK3CA (0.45) | PIK3CAPRMT5KCNH2SLC6A9 | |
| SCHEMBL9612576 | 0.81 | PIK3CA (0.45) | PIK3CAPRMT5KCNH2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885CREBBP 259/4885GPR142 1660/4885 |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885CREBBP 259/4885GPR142 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.